Roivant Posts $31M Q2 Revenue, Loss Narrower Than Street Expected
ROIV has more than doubled off its 52-week low of $19.79.
Summary
Roivant reported Q2 revenue of $35.1 million and a net loss of $137.211 million, or -$0.27 per basic share. The operating loss of $268.049 million came in well below the IBES estimate of -$336.3 million, a roughly $68 million favorable gap, with operating expenses at $303.17 million, and the lower than expected operating loss was driven by lower R&D expenses. The quarter follows the August FDA approval and commercial launch of Lisraya for dermatomyositis and positive Phase 3 CLARITY results for brepocitinib in October, so the top line is the first read on early Lisraya uptake. The company entered the quarter with a large liquidity cushion from the prior $950 million Moderna settlement, so the loss is not a funding concern.
At the time of this announcement, ROIV was trading at $40.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $28.1B. The 52-week trading range was $19.79 to $42.50. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.